<HashMap><database>GEO</database><file_versions><headers><Content-Type>application/xml</Content-Type></headers><body><files><Other>ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE345nnn/GSE345464/</Other></files><type>primary</type></body><statusCode>OK</statusCode><statusCodeValue>200</statusCodeValue></file_versions><scores/><additional><omics_type>Transcriptomics</omics_type><species> Mus musculus</species><species>Homo sapiens</species><gds_type> Genome binding/occupancy profiling by high throughput sequencing</gds_type><gds_type>Expression profiling by high throughput sequencing</gds_type><full_dataset_link>https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE345464</full_dataset_link><repository>GEO</repository><entry_type>GSE</entry_type></additional><is_claimable>false</is_claimable><name>Compartment-specific PPARδ activity controls the outcome of cancer – immune cell competition and immunotherapy efficacy</name><description>Most patients with solid tumors fail to sustain anti-tumor immunity, in part because immune cells cannot outcompete cancer cells inside the immunosuppressive tumor microenvironment. Here, we identify the lipid-sensing transcription factor PPARδ as a compartment-specific determinant of cancer-immune fitness balance and immunotherapy efficacy. Activating PPARδ in cancer cells promotes their growth and impairs anti-tumor immunity, whereas activating it in immune cells drives tumor suppression and overrides tumor-promoting effects of cancer-intrinsic activation.Mechanistically, PPARδ enhances CD8+ T cell fitness against cancer through effector-associated chromatin and remodeling and Cpt1a-mediated fatty acid oxidation, which is partly necessary but not sufficient.Therapeutically, PPARδ-activated CD8+ T cells sensitize immunotherapy resistant microsatellite stable (MSS) metastatic colorectal cancer to checkpoint blockade in mice, and pharmacologic or genetic PPARδ activation enhances human CAR-T cell function. These findings identify compartment-specific PPARδ activity as a targetable driver of immune cell fitness that can be harnessed to improve outcomes in immunotherapy-resistant tumors.</description><dates><publication>2026/08/31</publication></dates><accession>GSE345464</accession><cross_references><GSM>GSM10005097</GSM><GSM>GSM10005096</GSM><GSM>GSM10005099</GSM><GSM>GSM10005098</GSM><GSM>GSM10005093</GSM><GSM>GSM10005092</GSM><GSM>GSM10005095</GSM><GSM>GSM10005094</GSM><GSM>GSM10005091</GSM><GSM>GSM10005090</GSM><GSM>GSM10005127</GSM><GSM>GSM10005126</GSM><GSM>GSM10005123</GSM><GSM>GSM10005122</GSM><GSM>GSM10005089</GSM><GSM>GSM10005125</GSM><GSM>GSM10005124</GSM><GSM>GSM10005086</GSM><GSM>GSM10005085</GSM><GSM>GSM10005088</GSM><GSM>GSM10005121</GSM><GSM>GSM10005087</GSM><GSM>GSM10005120</GSM><GSM>GSM10005082</GSM><GSM>GSM10005081</GSM><GSM>GSM10005084</GSM><GSM>GSM10005083</GSM><GSM>GSM10005080</GSM><GSM>GSM10005119</GSM><GSM>GSM10005116</GSM><GSM>GSM10005115</GSM><GSM>GSM10005118</GSM><GSM>GSM10005117</GSM><GSM>GSM10005079</GSM><GSM>GSM10005112</GSM><GSM>GSM10005111</GSM><GSM>GSM10005078</GSM><GSM>GSM10005114</GSM><GSM>GSM10005113</GSM><GSM>GSM10005075</GSM><GSM>GSM10005074</GSM><GSM>GSM10005110</GSM><GSM>GSM10005077</GSM><GSM>GSM10005076</GSM><GSM>GSM10005071</GSM><GSM>GSM10005070</GSM><GSM>GSM10005073</GSM><GSM>GSM10005072</GSM><GSM>GSM10005109</GSM><GSM>GSM10005108</GSM><GSM>GSM10005105</GSM><GSM>GSM10005104</GSM><GSM>GSM10005107</GSM><GSM>GSM10005106</GSM><GSM>GSM10005101</GSM><GSM>GSM10005100</GSM><GSM>GSM10005103</GSM><GSM>GSM10005102</GSM><GPL>37309</GPL><GPL>37305</GPL><GSE>345464</GSE><taxon> Mus musculus</taxon><taxon>Homo sapiens</taxon></cross_references></HashMap>